ZA916661B - Stabilized solid chemical compositions - Google Patents

Stabilized solid chemical compositions

Info

Publication number
ZA916661B
ZA916661B ZA916661A ZA916661A ZA916661B ZA 916661 B ZA916661 B ZA 916661B ZA 916661 A ZA916661 A ZA 916661A ZA 916661 A ZA916661 A ZA 916661A ZA 916661 B ZA916661 B ZA 916661B
Authority
ZA
South Africa
Prior art keywords
water soluble
alkaline stabilizer
chemical compositions
solid chemical
stabilized solid
Prior art date
Application number
ZA916661A
Other languages
English (en)
Inventor
Pieter De Haan
De Haan Pieter
Cornelius Josephus Maria V Ven
Josephus Maria Van D Cornelius
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of ZA916661B publication Critical patent/ZA916661B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Lubricants (AREA)
ZA916661A 1990-09-13 1991-08-22 Stabilized solid chemical compositions ZA916661B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58185990A 1990-09-13 1990-09-13

Publications (1)

Publication Number Publication Date
ZA916661B true ZA916661B (en) 1992-06-24

Family

ID=24326864

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA916661A ZA916661B (en) 1990-09-13 1991-08-22 Stabilized solid chemical compositions

Country Status (14)

Country Link
EP (1) EP0475482B1 (xx)
JP (1) JP3153577B2 (xx)
KR (1) KR100196209B1 (xx)
AT (1) ATE112491T1 (xx)
AU (1) AU643920B2 (xx)
CA (1) CA2049811C (xx)
DE (1) DE69104453T2 (xx)
DK (1) DK0475482T3 (xx)
ES (1) ES2064887T3 (xx)
FI (1) FI104361B (xx)
IE (1) IE65274B1 (xx)
NZ (1) NZ239753A (xx)
PT (1) PT98955B (xx)
ZA (1) ZA916661B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6428894A (en) * 1993-03-26 1994-10-24 Franciscus W.H.M. Merkus Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine
JP2001518923A (ja) * 1997-03-26 2001-10-16 ダブリュ エイチ エム マーカス，フランシスカス 鼻腔用メラトニン組成物
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6691057B2 (en) 2001-02-26 2004-02-10 L.U.M. Gesellschaft Fur Labor- Umweltdiagnostic & Medizintechnik Mbh Method and device for accelerated stability analysis
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2873524C (en) 2006-05-04 2018-02-20 Boehringer Ingelheim International Gmbh A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
KR102416406B1 (ko) * 2019-09-24 2022-07-04 주식회사 종근당 티카그렐러의 산 부가염을 포함하는 안정화된 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2554736A (en) 1951-05-29 Tertiary aminoalkyl-iminodibenzyls
US2018410A (en) 1933-12-11 1935-10-22 Victor Chemical Works Dentifrice preparation
US2287699A (en) 1940-02-15 1942-06-23 Monsanto Chemicals Stabilized dicalcium phosphate
US3012852A (en) 1956-06-06 1961-12-12 Monsanto Chemicals Stabilized calcium phosphates and process therefor
DE1277222B (de) 1965-12-22 1968-09-12 Knapsack Ag Verfahren zur Stabilisierung von Dicalciumphosphatdihydrat
NL129434C (xx) 1966-03-12
US4128641A (en) 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
DE2648061C2 (de) 1976-10-23 1982-11-04 Hoechst Ag, 6000 Frankfurt Verfahren zum Stabilisieren von Di-calciumhydrogenphosphatdihydrat
DE2741513A1 (de) 1977-09-15 1979-03-22 Benckiser Gmbh Joh A Verfahren zum stabilisieren von calciumhydrogenphosphat-dihydrat gegen hydrolyse
IE52274B1 (en) 1980-12-12 1987-09-02 Stauffer Chemical Co A process of compacting fine particles of calcium phosphate and the compacts obtained thereby
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
GB8920693D0 (en) * 1989-09-13 1989-10-25 Nicholas Kiwi Pty Ltd Non-effervescent ibuprofen compositions

Also Published As

Publication number Publication date
DE69104453T2 (de) 1995-03-16
ATE112491T1 (de) 1994-10-15
FI104361B (fi) 2000-01-14
AU8341691A (en) 1992-03-19
IE913054A1 (en) 1992-02-25
AU643920B2 (en) 1993-11-25
ES2064887T3 (es) 1995-02-01
IE65274B1 (en) 1995-10-18
PT98955B (pt) 1999-02-26
EP0475482B1 (en) 1994-10-05
DE69104453D1 (de) 1994-11-10
NZ239753A (en) 1992-10-28
JPH0578236A (ja) 1993-03-30
PT98955A (pt) 1992-08-31
FI914147A (fi) 1992-03-14
DK0475482T3 (da) 1995-04-03
KR100196209B1 (ko) 1999-06-15
KR920005978A (ko) 1992-04-27
FI914147A0 (fi) 1991-09-03
JP3153577B2 (ja) 2001-04-09
EP0475482A1 (en) 1992-03-18
CA2049811C (en) 2002-11-05
CA2049811A1 (en) 1992-03-14

Similar Documents

Publication Publication Date Title
ZA916661B (en) Stabilized solid chemical compositions
KR0136279B1 (ko) 일정수분을 함유하는 서방형 제제
IL67172A (en) Derivatives of cis,endo-2-azabicyclo-(3.3.0)-octane-3-carboxylic acid,process for their preparation and pharmaceutical agents containing these compounds
KR910002670B1 (ko) 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법
KR920006909B1 (ko) 니트렌디핀을 함유하는 고상 약제의 제조 방법
AU751575B2 (en) Pharmaceutical levothyroxine preparation
MX9706062A (es) FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA.
MD1007C2 (ro) 1,3-Oxatiolan,izomeri geometrici şi optici ai lui,amestecurile acestor izomeri, procedeu de obţinere a lor şi compoziţie farmaceutică care manifestă activitate antivirotică
US4906647A (en) Stabilized pharmaceutical compositions
EG17589A (en) Process for preparing of 6-aryl 4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3h)-yl)-benzeneacetonitriles
AU742382B2 (en) Pharmaceutical preparation containing levothyroxine sodium
JPS5581596A (en) Composition for determining creatine kinase
NZ313576A (en) Stable solid formulation of enalapril salt and process for preparation thereof
HU901428D0 (en) Process for the preparation of 5-substituted 1,4-dihydro-4-oxo-naphthiridine-3-carboxylic acid derivatives
AU576386B2 (en) 1h-indol-3-yl containing 1,3-dimethyl-1h-purine-2,6-diones
HU905725D0 (en) Process for producing 1,4-disubstituted 5-aryl-carbamoyl-4(6)-oxo-6(4)-oxido-pyrimidine-betaine derivatives and anthelmintic preparatives containing these compounds as active substance
HU895241D0 (en) Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient
MY137475A (en) Chemical compounds.
ZA821036B (en) Acesulfam-containing compositions,tablets on the basis thereof and process for the manufacture of these tablets
NO177484C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat i form av myke kapsler
HUT56579A (en) Process for producing 19-norprogesterone derivatives alkylated at 17/21 position, as well as pharmaceutical compositions comprising such compounds as active ingredient
JPS55122713A (en) Tablet comprising antibacterial substance
ES8304924A1 (es) Un procedimiento para la preparacion de nuevos derivados del acido glutamil-diaminopimelico que contiene una b-lactama.
ES8502094A1 (es) Un procedimiento para la preparacion de derivados de tetrahidroisoquinolina.
ES8206510A1 (es) Procedimiento para la preparacion del compuesto 3-metil-3- (o-metoxi-fenoxi)-benzo-2,4-dioxaciclohexanona